Emicizumab Injection

DRUG2 trials

Sponsors

GWT-TUD GmbH, Dhaka Medical College

Conditions

Hemophilia AHemophilia A, Acquired

Phase 2

Emicizumab in Acquired Hemophilia A

CompletedNCT04188639

GWT-TUD GmbHHemophilia A, Acquired

Start: 2021-03-23End: 2023-01-04Updated: 2023-01-09

Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A Patients

Not yet recruitingNCT06938659

Dhaka Medical CollegeHemophilia A

Start: 2025-06-01End: 2026-07-31Target: 20Updated: 2025-04-22

Related Papers

Management of Breakthrough Bleeding During Emicizumab Prophylaxis in Acquired Haemophilia A: Data From the GTH‐AHA‐EMI Study

Haemophilia2026-06-15

Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A.

2025-11-01

Emicizumab Versus Immunosuppression for Acquired Hemophilia Α (AHA)

Blood2023-11-02

Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study.

2023-10-1633 citations